Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30686959 | 1.00 | KRAS (0.67) | KRAS | |
| SCHEMBL29125119 | 1.00 | KRAS (0.67) | KRAS | |
| SCHEMBL29914145 | 1.00 | KRAS (0.67) | KRAS | |
| SCHEMBL27003398 | 0.91 | KRAS (0.70) | KRAS | |
| SCHEMBL30717277 | 0.91 | KRAS (0.63) | KRAS | |
| SCHEMBL29634764 | 0.91 | KRAS (0.63) | KRAS | |
| SCHEMBL29940077 | 0.91 | KRAS (0.60) | KRAS | |
| SCHEMBL29939908 | 0.91 | KRAS (0.63) | KRAS | |
| SCHEMBL30717282 | 0.91 | KRAS (0.60) | KRAS | |
| SCHEMBL25981024 | 0.91 | KRAS (0.63) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4305038-A1 | KRAS G12D INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117242074-A | KRAS G12D inhibitors | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117177976-A | KRAS inhibitors | 百时美施贵宝公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.